great news.. also from bioshares on sat just passed .."the ACS...

great news..

also from bioshares on sat just passed ..
"the ACS market in the US for heparin products is estimated at $500m".

If you add in the "normal" heparin market you have an enormous potential market for ACL. Bioshares also pointed out that the recent apparent fall in Arixtra sales was not in fact a fall at all.

Put all this together with acl's freedom to do a new deal in the US and we may actually see something quicker than we thought .. equally this makes acl at 60 odd cents an extremely attractive target..

my opinion only